Abstract
Despite several technical improvements, peritonitis remains one of the major complications in paediatric, as well as in adult continuous peritoneal dialysis (CPD), i.e. continuous ambulatory (CAPD), and automated peritoneal dialysis (APD). The fact that this complication still constitutes one of the main causes of morbidity and technique failure [Edefonti 1996] highlights the need for optimal prevention and diagnosis, adequate treatment, and a balance between the goal of obtaining a high primary cure rate and the need to limit treatment side-effects. In paediatric patients, where hemodialysis (HD), for medical or psychosocial reasons, is not an equivalent option, the treatment and the prevention of peritonitis especially are key elements in the care of paediatric patients on CPD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Acar JF, Courvalin P, Chabbert YA. Methicillin-resistant staphylococcemia: bacteriological failure of treatment with cephalosporins. Antimicrob Agents Chemother 1970;4:280–285.
Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections. Treatment of tuberculosis and tuberculosis infection in adults and children. Clin Infect Dis 1995;21:9–27.
Akl K, Milder JE. Ketoconazole treatment of Candida peritonitis during continuous peritoneal dialysis. Pediatr Infec Dis 1984;3:487.
Alexander S. Peritoneal dialysis in children. In: Nolph KD, ed. Peritoneal Dialysis. Dordrecht; Kluwer Academic Publishers, 1989:343–364.
Alexander SR, Balfe JW, Harvey E. Peritoneal dialysis in children. In: Gokal R., Nolph KD, eds. The Textbook of Peritoneal Dialysis. Dordrecht; Kluwer Academic Publishers, 1994:591–637.
Al-Fadel Saleh M, Al-Quorain A, Larbi E, Al-Fawaz I, Taha O et al. Tuberculous peritonitis in children: report of two cases and literature review. J Pediatr Gastroen Nutr 1997;24:222–225.
Alpert GA, Campos JM, Harris MC, Preblud SR, Plotkin SA. Vancomycin dosage in paediatrics reconsidered. Am J Dis Child 1984;138:20–22.
Amon O, Oest K, Bitzan M, Müller-Wiefel DE; Teicoplanin (T), a suitable antibiotic to treat peritonitis in children on CAPD. Perit Dial Int 1992;12:(Suppl 2): s91.
Andreetta B, Verrina E, Sorino P, Edefonti A, Perfumo F et al. Complications linked to chronic peritoneal dialysis in children after kidney transplantation: experience of the Italian registry of pediatric chronic peritoneal dialysis. Perit Dial Int 1996;16(Suppl 1):s570–s573.
Andreoli SP, Langefeld CD, Stadler S, Smith P, Sears A et al. Risks of peritoneal membrane failure in children undergoing long-term peritoneal dialysis. Pediatr Nephrol 1993;7:543–547.
Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother 1992;36:1347–1351.
Atkins RC, Humphery T, Thomson N, Williamson J, Hooke D et al. Bacterial and “sterile” peritonitis. In: Atkins RC, Thomson NM, Farrell PC, eds.. Peritoneal dialysis. New York; Churchill Livingstone, 1981: 272–283.
Bailie GR, Kane MP. Stability of drug additives to peritoneal dialysate. Perit Dial Int 1995;15:328–335.
Bailie GR, Haqqie SS, Eisele G, Gorman T, Low CL. Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis. Perit Dial Int 1995;15:269–271.
Bald M, Rascher W, Bonzel KE, Müller-Wiefel DE. Pharmacokinetics of intraperitoneal cefotaxime in children with peritonitis undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1990;10:311–313.
Barza M, Ioannidis J, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a metaanalysis. Br Med J 1996;312:338–345.
Battista C, Kane MP, Moon DG, Bailie G. Stability of ofloxacin in peritoneal dialysis solutions. Perit Dial Int 1995;15:72–74.
Beaman M, Solaro L, McGonigle RJ, Michael J, Adu D. Vancomycin and ceftazidime in the treatment of CAPD peritonitis. Nephron 1989;51:51–55.
Beard-Pegler MA, Gabelish CL, Stubbs E, Harbour C, Robson J et al. Prevalence of peritonitis-associated coagulase-negative staphylococci on the skin of continuous ambulatory peritoneal dialysis patients. Epidem Inf 1989;102:365–378.
Beauchamp D, Thériault G, Grenier L, Gourde P, Perron S et al. Ceftriaxone protects against tobramycin nephrotoxicity. Antimicrob Agents Chemother 1994;38:750–756.
Bell MJ. Peritonitis in the newborn-current concepts. Pediatr Clin North Am 1985;32:1181–1201.
Benevent D, Lagarde C, Darins MC. Intraperitoneal route for vancomycin in CAPD patients. Nephron 1988; 49:173.
Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically III patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691–695.
Bennett-Jones DN, Russell GI, Barrett A. A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. J Antimicrob Chemother 1990;26:73–76.
Bennett WM. Editorial review: mechanisms of aminoglycoside nephrotoxicity. Clin Exp Pharmacol 1989;16:1–6.
Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996;27:695–700.
Bezerra DA, Silva MB, Caramon JS, Sugizaki MF, Sadatsune T et al. The diagnostic value of Gram stain for initial identification of the etiologic agent of peritonitis in CAPD patients. Perit Dial Int 1997;17:269–272.
Blowey DL, Warady BA, McFarland SK. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Adv Perit Dial 1994;10:297–299.
Boeschoten EW, Rietra PJ, Krediet RT, Visser MJ, Arisz L. CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 1985;16:789–797.
Boeschoten EW, Struijk DG, Kuijper EJ, Buijsen C. Cephradine as first-line antibiotic for the treatment of CAPD-peritonitis. Perit Dial Int 1995;15(Suppl 1):s23.
Boeschoten EW. Long-term consequences of peritonitis. Perit Dial Int 1996;16(Suppl 1):s349–s352.
Borghol M, Alrabeeah A. Entrapment of the appendix and the fallopian tube in peritoneal dialysis catheters in two children. J. Pediatr Surg 1996;31:427–429.
Bosso JA, Black PG. The use of aztreonam in pediatric patients: a review. Pharmacotherapy 1991;11:20–25.
Bouvier d’Yvoire MJ, Maire PH. Dosage regimens of antibacterials. Implications of a pharmocokinetic/pharmacodynamic model. Clin Drug Invest 1996;11:229–239.
Bouza P, Garcia Falcon T, Pérez Fontán M, Rodríguez-Carmona A, López Vázquez M et al. Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. Adv Perit Dial 1996; 12:185–188.
Bowley JA, Pickering SJ, Scantlebury AJ, Ackrill P, Jones DM. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1988;21 (Suppl A):s133–s139.
Boyce NW, Wood C, Thomson N, Kerr P, Atkins RC. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis — A prospective, randomized comparison of intermittentv continuous therapy. Am J Kidney Dis 1988;12:304–306.
Braun A, Querfeld U, Mehls O. “Sterile peritonitis” caused by varicella in a child on maintenance peritoneal dialysis treatment. Pediatr Nephrol 1991;5:95–96.
Brauner L, Kahlmeter G, Lindholm T, Simonsen O. Vancomycin and netilmicin as first line treatment of peritonitis in CAPD patients. J Antimicrob Chemother 1985;15:751–758.
Brier ME, Aronoff GR. Initial intraperitoneal therapy for CAPD peritonitis: the network 9 peritonitis study. Adv Perit Dial 1994;10:141–143.
Brown AL, Stephenson JR, Baker LR, Tabaqchali S. Epidemiology of CAPD-associated peritonitis caused by coagulase-negative staphylococci: comparison of strains isolated from hands, abdominal Tenckhoff catheter exit site and peritoneal fluid. Nephrol Dial Transplant 1991;6:643–648.
Buggy BP, Schaberg DR, Swartz RD. Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am J Med 1984;76:1035–1040.
Buggy BP. Culture methods for continuous ambulatory peritoneal dialysis-associated peritonitis. Clin Microbiol Newslett 1986;8:12–14.
Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: Gram negatives versus Gram positives in the network 9 peritonitis study. Kidney Int 1997;52:524–529.
Buring JE, Evans DA, Mayrent SL, Rosner B, Colton T et al. Randomized trials of aminoglycoside antibiotics: quantitative overview. Rev Infect Dis 1988;10:951–957.
Bums JL, Malhotra U, Lingappa J, Smith S. Unusual presentations of nontuberculous mycobacterial infections in children. Pediatr Infect Dis J 1997;16:802–806.
Buttler WT, Bennet JE, Alling DW, Wertlake PT, Utz JP et al.. Nephrotoxicity of amphotericin B: Early and late effects in 81 patients. Ann Intern Med 1964;61:175–187.
Cairns CJ, Robertson J. Incompatibility of ceftazidime and vancomycin. Pharm J 1987;238:577.
Cairns H, Beckett J, Rudge CJ, Thompson FD, Mansell MA. Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis. Clin Neph 1989;32:27–30.
Calame W, Hendrickx RJ, Namavar F, Oe LP, Beelen RH. Effect of glucose in dialysis fluid on antibacterial defence in the peritoneal cavity. J Infect 1995;30:227–233.
Cameron JS. Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Pediatr Nephrol 1995;9:647–662.
Cancarini GC, Manili L, Brunori G, Camerini C, Zubani R et al. Simultaneous catheter replacement-removal during infectious complications in peritoneal dialysis. Adv Perit Dial 1994;10:210–213.
Cantú TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18:4:533–543.
Cappelletty DM, Kang SL, Palmer SM, Rybak MJ. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995;33:1797–1801.
Caramori JT, Barrose Silva M, Felipe MJ, Sadatsune T, Montelli AC et al. Successful treatment of fungal peritonitis in CAPD by intravenous, intraperitoneal and intracatheter administration of amphotericin B. A case report. Peri Dial Int 1995;15:187–188.
Chadwick EG, Yogev R, Shulman ST. Combination antibiotic therapy in pediatrics. Am J Med 1986;80(Suppl 6B):166–171.
Chadwick D, Turner K, Hair M, McEwen A, Gokal R. Outcome of peritonitis treated with intraperitoneal (IP) weekly vancomycin and daily IP netilmicin. Perit Dial Int 1995;15(Suppl 1):s24.
Chambers HF. Coagulase-negative staphylococci resistant toβ-lactam antibiotics in vivo produce penicillin-binding protein 2a. Antimicrob Agents Chemother. 1987;31:1919–1924.
Chambers HF. Methicillin-resistant staphylococci. Clin Microb Rev 1988;1:173–186.
Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. Drug Intell Clin Pharm 1989;23:788–794.
Chan MK, Chan PC, Cheng IP, Chan CY, Ng WS. Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment. Nephrol Dial Transplant 1989;4:814–817.
Chan MK, Cheng IK, Ng WS. A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990;15:155–159.
Chan TM, Chan CY, Cheng SW, Lo WK, Lo CY et al. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. Nephrol Dial Transplant 1994;9:539–542.
Chardot C, Iskandarani F, De Dreuzy O, Duquesne B, Pariente D et al. Spontaneous perforation of the biliary tract in infancy: a series of 11 Cases. Eur J Pediatr Surg 1996;6:341–346.
Chen TF, Collier DS. Intraperitoneal rupture of an infected urachal cyst in an infant. Eur J Sur 1991;157:67–68.
Cheng IK, Chan PC, Chan MK. Tuberculous peritonitis complicating long-term peritoneal dialysis. Am J Nephrol 1989;9:155–161.
Cheng IK, Fang GX, Chan TM, Chan PC, Chan MK. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. QJ Med 1989;71:407–416.
Cheng IK, Chan CY, Wong WT, Cheng SW, Ritchie CW et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 1993;13(Suppl 2):s351–s354.
Chiou YY, Chen WP, Yang LY, CAPD Team, Lin CY. Peritonitis in children being treated with continuous ambulatory peritoneal dialysis. Acta Paediatr Sin 1995;36:176–183.
Chong TK, Piraino B, Bernardini J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int 1991;11:152–155.
Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of staphylococcus epidermidis to smooth surfaces. Infect Immun 1982;37:318–326.
Chung KC, Gill MA. Continuous vs. intermittent administration of antimicrobial agents. J Infect Dis Pharmocother 1995;1:25–44.
Churchill DN, Taylor DW, Vas SI, Singer J, Beecroft ML et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: a randomized clinical trial of cotrimoxazole prophylaxis. Perit Dial Int 1988;8:125–128.
Churchill DN, Taylor DW, Vas SI, Oreopoulos D. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Perit Dial Int 1989;9:159–163.
Coles GA, for the Mupurocin Study Group. The effect of intranasal mupirocin on CAPD exit site infection (ESI). J Am Soc Nephrol 1994;5:439.
Coles GA, Gokal R, Ogg C, Jani F, O’Donoghue DT et al. A randomized controlled trial of a bicarbonate-and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 1997;17:48–51.
Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 1997;17:373–378.
Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 1995;7(Suppl 2):s47–s52.
Currie DC, Higg E, Metcalfe S, Roberts DE, Cole PC. Simple method of monitoring colonising microbial load in chronic bronchial sepsis: pilot comparison of reduction in colonising microbial load with antibiotics given intermittently and continuously. J Clin Pathol 1987;40:830–836.
Currier H. Chylous Ascites: an unexpected complication that resembles peritonitis. Anna J 1995;22:157–159.
Dabbagh S, Fassinger N, Clement K, Fleischmann LE. The effect of aggressive nutrition on infection rates in patients maintained on peritoneal dialysis. Adv Perit Dial 1991;7:161–164.
Darouiche RO, Dhir A, Miller AJ, Landon GC, Raad II et al. Vancomycin penetration into biofilm covering infected protheses and effect on bacteria. J Infect Dis 1994;170:720–723.
Dasgupta MK, Shishido H, Salama S, Singh R, Larabie M et al. The effects of macrolide and quinolone antibiotics in methicillin-resistant Staphylococcus aureus biofilm growth. Adv Perit Dial 1997;13:214–217.
Davics SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498–506.
de Fijter CW, Oe LP, Heezius EC, Donker AJ, Verbrugh HA. Low-calcium peritoneal dialysis fluid should not impact peritonitis rates in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996;27:409–415.
Dórea EL, Yu L, De Castro I, Campos SB, Ori M et al. Nephrotoxicity of Amphotericin B is attenuated by solubilizing with Lipid emulsion. J Am Soc Nephrol 1997;8:1415–1422.
Drew PJ, Casewell MW, Desai N, Houang ET, Simpson CN et al. Cephalexin for the oral treatment of CAPD peritonitis. J Antimicrob Chemother 1984; 13:153–159.
Dryden M, Eykyn SJ. Short-course gentamicin in gram-negative CAPD peritonitis. Lancet 1993;341:497.
Edefonti A, Consalvo G, Pappalettera M. Infectious complications in paediatric patients treated with chronic peritoneal dialysis (CPD). Perit Dial Int 1996;16(Suppl. 1):s543–s547.
Editorial. Nosocomial enterococci resistant to vancomycin — United States, 1989–1993. MMWR 1993;42:597–599.
Editorial. Cooperative study helps specialists analyze success of PD in children. Nephrol News Issues 1996;10:50–52.
Editorial. CDC Update. Staphylococcus aureus with reduced susceptibility to vancomycin — United States 1997. MMWR 1997;46:813.
Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329–334.
Edwards R, Thompson RC, Finch RG. Antibiotic susceptibility of staphylococci from CAPD peritonitis in children. J Antimicrob Chemother 1987;20:138–139.
Enriquez JL, Kalia A, Travis LB. Fungal peritonitis in children on peritoneal dialysis. J Pediatr 1990;117:830–832.
Erdman SM, Rodvold KA, Pryka RD. An updated comparison of drug dosing methods part III: aminoglycoside antibiotics. Clin Pharmacokinet 1991;20:374–388.
Fabris A, Biasioli S, Borin D, Brendolan A, Chiaramonte S et al. Fungal peritonitis in peritoneal dialysis: our experience and review of treatments. Perit Dial Bull 1984;4:75–77.
Fang LJ, Tsau YK, Chen CH, Lee CY. Peritonitis in children with nephrotic syndrome. Acta Paed Sin 1991;32:265–271.
Fang GX, Lo WK, Chan TM, Chau PY, Choy BY et al. A randomized prospective comparison of oral versus intraperitoneal of loxacin as primary treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Abstracts 6th Asian Pacific Congress of Nephrology 1995;126.
Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23:138–141.
Farber BF, Kaplan MH, Clogston AG Staphylococcus epidermidis extracted slime inhibits the antimicrobial action fo glycopeptide antibiotics. J Infect Dis 1990;161:37–40.
Feinstein EI, Chesney RW, Zelikovic I. Peritonitis in childhood renal disease. Am J Nephrol 1988;8:147–165.
Fenton S, Wu G, Cattran D, Wadgymar A, Allen AF. Clinical aspects of peritonitis in patients on CAPD. Perit Dial Bull 1981;1(Suppl.1):s4–s6.
Fields SM. Review of vancomycin pharmacokinetics and toxicity with emphasis on the neonate. CSHP Voice 1986;13:57–60.
Finch RG, Edwards R, Filik R., Wilcox MH. Continuous ambulatory peritoneal dialysis (CAPD) peritonitis: the effect of antibiotic on the adherence of coagulase-negative staphylococci to silicone rubber catheter material. Perit Dial Int 1989;9:103–105.
Fine RN, Salusky IB, Hall T, Lucullo L, Jordan SC et al. Peritonitis in children undergoing continuous ambulatory peritoneal dialysis. Pediatrics 1983;71:806–809.
Fisher FP, Schenk U, Kiefer T et al. In vitro effects of bicarbonate versus lactate buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Am J Kidney Dis 1995;26:924–933.
Fleming LW, Moreland TA, Scott AC, Stewart WK, White LO. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continous ambulatory peritoneal dialysis. J Antimicrob Chemother 1987;19:493–503.
Fleming LW, Phillips G, Stewart WK, Scott AC. Oral ciprofloxacin in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1990;25:441–448.
Flynn JT, Meislich D, Kaiser BA, Polinsky MS, Baluarte HJ. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Perit Dial Int 1996;16:52–57.
Ford DM. Basic mechanisms of aminoglycoside toxicity. Pediat Nephrol 1994; 8:635–640.
Fossum RM, Descheneaux KA. Blunt trauma of the abdomen in children. J Forensic Sci 1991;36:47–50.
Frongillo RF, Donati L, Federico G, Martino P, Moroni M et al. Clinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-resistant strains. Antimicrob Agents Chemother 1986;29:789–796.
Gagnon RF, Kostiner GB, Richards GK. The susceptibility of staphylococcus epidermidis biofilms to aminoglycoside antibiotics modified by peritoneal dialysis solutions. Perit Dial Int 1992; 12(Suppl 2):s63.
Gaillard JL, Merlino RM, Pajot N, Goulet O, Fauchere JL et al. Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. J Parenter Enteral Nutr 1990;14:593–597.
Ganga UR, Schafer L. Tuberculous peritonitis: a case report and literature review. SDJ Med 1992;45:287–289.
Garcia-Lopez E, Mendoza-Guevara L, Morales A, Aguilar-Kitzu A, Vicencio LM et al. Comparison of peritonitis rates in children on CAPD with spike connector versus two disconnect systems. Adv Perit Dial 1994;10:300–303.
Gendeh BS, Said H, Gibb AG, Aziz NS, Kong N et al. Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis. J Laryngol Otol 1993;107:681–685.
Ghoshal UC, Poddar U, Yaccha SK. Spontaneous bacterial peritonitis in a child with abdominal lymphoma. Acta Oncol 1995;34:531.
Gilbert DN. Minireview. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399–405.
Goel S, Kathuria P, Moore HL, Prowant BF, Nolph KD. The effect of peritonitis on the peritoneal membrane transport properties in patients on CAPD. Adv Perit Dial 1996; 12:181–184.
Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32:325–334.
Gokal R. Risks of tobramycin use in CAPD patients with peritonitis. Perit Dial Bull 1982;2:139–140.
Gokal R, Mistry CD, Peers EM, and the Midas Study Group. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. Perit Dial Int 1995;15:226–230.
Goldraich I, Mariano M, Rosito N, Goldraich N. One-step peritoneal catheter replacement in children. Adv Perit Dial 1993;9:325–328.
Golper TA, Hartstein AI, Morthland VH, Christensen JM. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1987;31:1787–1790.
Golper TA, Tranæus AP. Vancomycin revisited. Perit Dial Int 1996;16:116–117.
Golper T. Intermittent versus continuous antibiotics for PD-related peritonitis. Perit Dial Int 1997; 17:11–12.
Gorensek MJ, Lebel MH, Nelson JD. Peritonitis in children with nephrotic syndrome. Pediatrics 1988;81:849–856.
Govaerts PJ, Claes J, Van de Heyning PH, Jorens PhG, Marquet J et al. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990;52:227–251.
Grable MS, Moazam F. Acute scrotal lesion secondary to barium peritonitis in an infant. Urology 1985;25:499–501.
Gruer LD, Kiddy K, Adu D, Michael J. Once-daily antibiotic treatment of CAPD peritonitis. Lancet 1984;ii:1282–1283.
Gruer LD, Turney JH, Curley J, Michael J, Adu D. Vancomycin and tobramycin in the treatment of CAPD peritonitis. Nephron 1985;41:279–282.
Gucek A, Bren AF, Lindic J, Hergouth V, Mlinsek D. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients? Adv Perit Dial 1994;10:144–146.
Gucek A, Bren AF, Hergouth V, Lindic J. Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. Adv Perit Dial 1997;13:218–220.
Hakim A, Hisam N, Reuman PD. Environmental Mycobacterial Peritonitis complicating peritoneal dialysis: three cases and review. Clin Infect Dis 1993;16:426–431.
Hanberger H, Nilsson LE. Retain intermittent dosing of carbapenems. Antimicrob Agents Chemother 1994;38:159–160.
Hancock K, Hulme B. Treatment of CAPD peritonitis with oral ciprofloxacin. Nephrol Dial Transplant 1989;4:759.
Hanevold CD, Fisher MC, Waltz R, Bartosh S, Baluarte HJ. Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis. Pediatr Nephrol 1995;9:609–611.
Hellinger WC, Rouse MS, Rabadan PM, Henry NK, Steckelberg JM et al. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob Agents Chemother 1992;36:1272–1275.
Herschkowitz S, Mizrahi S, Sujov P. Meconium peritonitis: a benign course in premature infant. Am J Perinatol 1990;7:31–32.
Ho-dac-Pannekect MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of GA125 in peritoneal effluent. Kidney Int 1997;51:888–889.
Holley HP, Tucker CT, Moffatt TL, Dodds KA, Dodds HM. Tuberculous peritonitis in patients undergoing chronic home peritoneal dialysis. Am J Kidney Dis 1982;1:222–226.
Honda M, Litaka K, Kawaguchi H, Hoshii S, Akashi S et al. The Japanese national registry data on pediatric CAPD patients: a ten-year experience — A report of the study group of pediatric PD conference. Perit Dial Int 1996;16:269–275.
Hospital infection control practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: recommendations of the hospital infection control practices advisory committee (HICPAC). Am J Infect Control 1995;23:87–94.
Howard RL, Millspaugh J, Teitelbaum I. Adult and pediatric peritonitis rates in a home dialysis program: comparison of continuous ambulatory and continuous cycling peritoneal dialysis. Am J Kidney Dis 1990;16:469–472.
Huang MY, Schacht J. Drug-induced ototoxicity. Pathogenesis and prevention. Med Toxicol Adverse Drug Exp. 1989;4:452–467.
Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988;33:900–911.
Innes A, Burden RP, Finch RG, Morgan AG. Treatment of resistant peritonitis in continuous ambulatory peritonea] dialysis with intraperitoneal urokinase: a double-blind clinical trial. Nephrol Dial Transplant 1994;9:797–799.
Ishizaki M, Oikawa K, Miyashita E. Usefulness of the endotoxin test for assessing CAPD peritonitis by Gram-negative organisms. Adv Perit Dial 1996;12:199–202.
Janicka L, Majdan M, Solski J, Baranowska E. Changes in peritoneal transport following the use of intraperitoneal gentamicin. Perit Dial Int 1994;14:168–170.
Janknegt R. CAPD peritonitis and fluoroquinolones: a review. Perit Dial Int 1991; 11:53–58.
John JF, McNeill WF. Activity of cephalosporins against methicillin-susceptible and methicillin resistant, coagulase-negative staphylococci: minimal effect of beta-lactamase. Antimicrob Agents Chemother 1980;17:179–183.
Johnson CA, Zimmerman SW, Rogge M. The pharmacokinetics of antibiotics used to treat peritoneal dialysis-associated peritonitis. Am J Kidney Dis 1984;4:3–17.
SJohnson CA, Zimmerman SW, Rogge M. Pharmacokinetics of oral cephradine in continuous ambulatory peritoneal dialysis patients. Nephron 1984;38:57–61.
Johnson RJ, Ramsey PG, Gallagher N, Ahmad S. Fungal peritonitis in patients on peritoneal dialysis: incidence, clinical features and prognosis. Am J Nephrol 1985;5:169–175.
Johnson CA, Zimmerman SW, Piraino B. Intraperitoneal vancoled does not cause chemical peritonitis-Response to Drs. Johnson and Zimmerman. Perit Dial Int 1989;9:225.
Jörres A, Topley N, Witowski J et al. Impact of peritoneal dialysis solutions on peritoneal immune defence. Perit Dial Int 1993;13(Suppl 2):s291–s294.
Juergensen PH, Juergensen DM, Wuerth DB, Finkelstein SH, Steele TE et al. Psychosocial factors and incidence of peritonitis. Adv Perit Dial 1996;12:196–198.
Kahlmeter G, Dahlager JI. Aminoglycoside toxicity — a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(Suppl A):s9–22.
Kalya AV, Aheam DG. Increased resistance to antifungal antibiotics of Candida spp. adhered to silicone. J Ind Microbiol 1995;6:451–455.
Kant SK, Goetz D, Marzluff C, Motz D. Relapsing peritonitis in continuous ambulatory peritoneal dialysis (CAPD): treatment by interruption of CAPD and prolonged antiobiotic therapy. Perit Dial Int 1988;8:155–157.
Kaplan RA, Alon U, Hellerstein S, Warady BA. Unusual Causes of peritonitis in three children receiving peritoneal dialysis. Perit Int Dial 1993;13:60–63.
Karanfil LV, Murphy M, Josephson A et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195–200.
Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983;98:447–455.
Keane WF, Everett ED, Fine RN, Golper TA, Vas SI et al. CAPD related peritonitis management and antibiotic therapy recommendations. Perit Dial Bull 1987;7:55–68.
Keane WF, Everett ED, Fine RN, Golper TA, Vas S et al. Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. Perit Dial Int 1989;9:247–256.
Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C et al. Peritoneal dialysis-related peritonitis treatment recommendations 1993 update. Perit Dial Int 1993;13:14–28.
Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996;16:557–573.
Keller E, Reetze P, Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1990;18:104–117.
Kemper MJ, Meyer-Jark T, Müller-Wiefel DE. IgG2 deficiency in uremic children is not restricted to peritoneal dialysis treatment. Pediatr Nephrol 1997;11:684–686.
Keogh JA, Carr ME, Murray F, McEvoy M, Grant G et al. Treatment of fungal peritonitis in CAPD patients using peritoneal lavage. Perit Dial Bull 1985;5:67–69.
Kerr CM, Perfect JR, Craven PC, Jorgensen JH, Drutz DJ et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med 1983;99:334–337.
Khanna R, Nolph KD, Prowant BF, Twardowski ZJ. Computer interaction: peritonitis. Adv Perit Dial 1994;10:19–21.
Kimber CP, Hutson JM. Primary peritonitis in children. Aust New Zealand J Surg 1996,66:169–170.
Kingwatanakul P, Warady B. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis. Adv Perit Dial 1997;13:281–284.
Klaus G, Schaefer F, Querfeld U, Soergel M, Wolf S et al. Treatment of relapsing peritonitis in pediatric patients on peritoneal dialysis. Adv Perit Dial 1992;8:302–305.
Klaus G, Schaefer F, Müller-Wiefel D, Mehls O and members of APN. Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Adv perit Dial 1995;11:296–301.
Knight M, Christopher MA. Drugs especially common in the pediatric intensive care unit. Prob Crit Care 1987;1:215–250.
Kravitz SP, Berry PL. Successful treatment of Aspergillus peritonitis in a child undergoing continuous cycling peritoneal dialysis. Arch Intern Med 1986;146:2061–2062.
Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 1987; 17:43–52.
Kuzion B, Lu-Melocoton T, Holloway M, Ingles S, He-Jing et al. Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution. Pediatr Nephrol 1995;9:12–17.
Lai MN, Kao MT, Chen CC, Cheung SY, Chung WK. Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis. Perit Dial Int 1997;17:87–89.
Lameire N, Belpaire F. Pharmacokinetics of antibiotics against Gram-negative infections in continuous peritoneal dialysis patients. Perit Dial Int 1993;13(Suppl 2):s371–s376.
Lameire N, Vogelaers D, Verschraegen G, Veys N. Vancomycin resistant enterococci — a threat to the nephrologist on the horizon? Glycopeptide-resistant enterococci and ICDC-recommendations for a limited use of glycopeptides. Nephrol Dial Transplant 1996; 11:2402–2406.
Lameire N, van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Perit Dial Int 1997;17(Suppl 2):s102–s110.
Larcher VF, Manolaki N, Vegnente A, Vergani D, Mowat AP. Spontaneous bacterial peritonitis in children with chronic liver disease: Clinical features and etiologic factors. J Pediatr 1985;106:907–912.
Latta K, Offner G, Brodehl J. Continuous peritoneal dialysis in children. Adv Perit Dial 1992;8:406–409.
Lee SH, Chiang SS, Hseih SJ, Shen HM. Intracatheter amphotericin B retention for fungal peritonitis in continuous ambulatory peritoneal dialysis. J Formos Med Assoc 1995;94:132–134.
Lee SH, Huang TS. Persistant eosinophilic peritonitis associated with funal infection cured by resection of external Tenckhoff catheter: a case report. Perit Dial Int 1997;17:397–399.
Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986;80:98–104.
Levy M, Balfe JW, Geary DF, Fryer-Keene SP, Bannatyne RM. Peritonitis in children undergoing dialysis. Child Nephrol Urol 1988-89;9:235–258.
Levy M, Balfe JW, Geary D, Fryer-Keene SP. Factors predisposing and contributing to peritonitis during chronic peritoneal dialysis in children: a ten-year experience. Perit Dial Int 1990;10:263–269.
Lewis MA, Smith T, Roberts D. Peritonitis, functional catheter loss and the siting of the dacron cuff in chronic peritoneal dialysis catheters in children. Eur J Pediatr Surg 1996;6:285–287.
Lewis MA, Smith T, Postlethwaite RJ, Webb NJA. A comparison of double-cuffed with single-cuffed Tenckhoff catheters in the prevention of infection in pediatric patients. Adv Perit Dial 1997;13:274–276.
Livingston DH, Wang MT. Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock. Am J Surg 1993; 165(2):203–207.
Locatelli A, Alvarez Quiroga M, De Benedetti L, Gomez M, Barone R et al. Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter. Adv Perit Dial 1995;11:177–179.
Loeppky C, Tarka E, Everett ED. Compatibility of cephalosporins and aminoglycosides in peritoneal dialysis fluid. Perit Dial Bull 1983;3:128–129.
Low CL, Eisele G, Cerda J, Venezia RA, Hanley E et al. Low prevalence of vancomycin-resistant enterococcus in dialysis outpatients with a history of vancomycin use. Perit Dial Int 1996;16:651–652.
Low CL, Bailie GR, Evans A, Eisele G, Venezia RA. Pharmacokinetics of once-daily IP gentamicin in CAPD patients. Perit Dial Int 1996;16:379–384.
Ludlam H, Dickens A, Simpson A, Phillips I. A comparison of tour culture methods for diagnosing infection in continuous ambulatory peritoneal dialysis. J Hosp Infec 1990;16:263–269.
Ludlam HA, Barton I, White L, McMullin C, King A et al. Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother 1990;25:843–851.
Ludlam H, Tremlett CH, Wilson APR. Preventing infection with Staphylococcus aureus in CAPD. Perit Dial Int 1997;17:405–406.
Lui SL, Lo CY, Choy BY, Chan TM, Lo WK et al. Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996;28:747–751.
Lum, GM. Peritonitis in infants and children on CAPD/CCPD. In: Fine RN, ed. Chronic ambulatory peritoneal dialysis (CAPD) and chronic cycling peritoneal dialysis (CCPD)in children. Boston; Martinus Nijhoff Publishing, 1987:189–200.
Lye WC, Lee EJ, van der Straaten J. Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 1993;13(Suppl 2):s348–s350.
Lye WC, Wong PL, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv Perit Dial 1995;11,179–181.
Lye WC, Leong SO, Lee EJ. Methicillin-resistant Staphylococcus aureus nasal carriage and infections CAPD. Kidney Int 1996;43:1357–1362.
Mallat SG, Brensilver JM. Tuberculous peritonitis in a CAPD patient cured without catheter removal: case report, review of the literature, and guidelines for treatment and diagnosis. Am J Kidney Dis 1989;13:154–157.
Maller R, Ahme H, Holmen C et al. Once-versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993;31:939–948.
Mancini ML, Dello Strologo L, Bianchi, et al. Sensineuronal hearing loss in patients reaching chronic renal failure in childhood. Pediatr Nephrol 1996;10:38–40.
Mannenbach M, Leichter H, Sheth K. Peritonitis in children with nephrotic syndrome. Wisconsin Med J 1988;87:21–23.
Marra F, Cairns B, Jewesson P. Vancomycin serum concentration monitoring. Clin Drug Invest 1996;120:105–118.
McAllister TA, Mocan H, Murphy AV, Beattie TJ. Antibiotic susceptibility of staphylococci from CAPD peritonitis in children. J Antimicrob Chemother 1987;19:95–100.
McCracken GH. Aminoglycoside toxicity in infants and children. Am J Med 1986;80:172–178.
Medcalf JF, Harris K, Walls J. Preserving the peritoneum in CAPD. Nephrol Dial Transplant 1997;12:393–394.
Mendoza L, Diaz Ponce H, Garcia E, Santos D, Amato D. Successful use of fluconazol in fungal peritonitis in pediatric patients. Perit Dial Int 1993;13(Suppl 1):s51.
Menzies RE, Cornere BM, MacCulloch D. Cephalosporin susceptibility of methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother 1987;31:42–45.
Meyers BR. Comparative toxicities of third-generation cephalosporins. Am J Med 1985;79(Suppl 2A): s96–103.
Millikin SP, Matzke GR, Keane WF. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1991;11:252–260.
Mirza K, Elzouki AY. Peritonitis in continuous ambulatory peritoneal dialysis in children living in Saudi Arabia. Pediatr Nephrol 1997;11:325–327.
Mocan H, Murphy AV, Beattie TJ, McAllister TA. Fungal peritonitis in children on continuous ambulatory peritoneal dialysis. Scot Med J 1989;34:494–496.
Montenegro J, Aguirre R, González O, Martinez I, Saracho R. Fluconazole treatment of Candida peritonitis with delayed removal of the peritoneal dialysis catheter. Clin Nephrol 1995;44:60–63.
Morse GD, Nairn DK, Walshe JJ. Once weekly intraperitoneal therapy for Gram-positive peritonitis. Am J Kidney Dis 1987;10:300–305.
Morton LP, Reynolds L, Zent R, Rayner BL. Hearing thresholds in CAPD patients.. Adv Perit Dial 1992; 8: 150–152.
Mouton JW, Horrevorts AM, Mulder PG, Prens EP. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990;34:2307–2311.
Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38: 931–936.
Mouton JW, Vinks AA. Is continuous infusion of ß-lactam antibiotics worthwhile?-efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996;38:5–15.
Mulhern JG, Braden GL, O’Shea MH, Madden RL, Lipkowitz GS et al. Trough serum vancomycin levels predict the relapse of Gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995;25:611–615.
Murugasu B, Conley SB, Lemire JM, Portman RJ. Fungal peritonitis in children treated with peritoneal dialysis and gastrostomy feeding. Pediatr Nephrol 1991; 5:620–621.
Nadig C, Binswanger U, von Feiten A. Is heparin therapy necessary in CAPD peritonitis? Perit Dial Int 1997;17:493–496.
Naziri W, Cheadle WG, Trachtenberg LS, Montgomery WD, Polk HC. Increased antibiotic effectiveness in a model of surgical infection through continuous infusion. Am Surg 1995;61:11–15.
Neiberger R, Aboushaar MH, Tawan M, Fennell R, Iravani A et al. Peritonitis in children on chronic peritoneal dialysis: analysis at 10 years. Adv Perit Dial 1991;7:272–274.
Niaudet P, Berard E, Revillon Y, Lothon M, Broyer M. Sclerosing encapsulating peritonitis in children. Contrib Nephrol 1987;57:230–238.
Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996;40:61–64.
Nikolaidis P, Vas S, Lawson V, Kennedy-Vosu L, Bernard A et al. Is intraperitoneal tobramycin ototoxic in CAPD patients? Perit Dial Int 1991;11:156–161.
Nishi A, Ito Y, Amamoto Y, Aida K, Kato H. Longitudinal changes in peritoneal equilibration test with or without peritonitis in children. Pediatr Nephrol 1995;9:562–565.
Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195–198.
Nye KJ, Gibson SP, Nwosu AC, Manji MR, Robinson BH et al. Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients: preliminary report. Perit Dial Int 1993;13:59–60.
Obst G, Gagnon RF, Prentis J, Richards GK. Comparative study of antibiotic activity against staphylococcus epidermidis biofilms. Adv Perit Dial 1988;4:273–277.
Odio C, McCracken GH, Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984;105:491.
Offner G, Latta K, Filler G. Peritonitis in paediatric CAPD/CCPD with different techniques. Perit Dial Int 1993;13(Suppl 1):s57.
Ogbevoen JO, Jaffe DM, Langer JC. Intraperitoneal rupture of an infected urachal cyst; a rare cause of peritonitis in children. Pediatr Emerg Care 1996;12:41–43.
Oh SH, Conley SB, Rose GM, Rosenblum M, Kohl S et al. Fungal peritonitis in children undergoing peritoneal dialysis. Pediatr Infect Dis 1985;4:62–66.
Paap CM, Nahata MC, Mentser MA, Mahan JD, Puri SK et al. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients. Ann Pharmacother 1992;26:341–343.
Pagniez DC, MacNamara E, Fortin F, Delvallez L, Fruchart A et al. Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis. Br Med J 1988;297:1174–1175.
Pasadakis P, Thodis E, Eftimimiadou A, Panagoutsos S, Papazoglou D. Treatment and prevention of relapses of CAPD Pseudomonas peritonitis. Adv Perit Dial 1993;9:206–210.
Pérez-Fontán M, Rosales M, Rodríguez-Carmona A, Garcia-Falcón T, Adeva M et al. Treatment of peritonitis in CAPD with ciprofloxacin: long-term experience. Adv Perit Dial 1993;9:211–214.
Pérez-Fontán M, Garcia-Falcón T, Rosales M, Rodríguez-Carmona A, Adeva M et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with Mupirocin: long-term results. Am J Kidney Dis 1993;22:708–712.
Piraino B, Bernardini J, Johnston J, Sorkin M. Chemical peritonitis due to intraperitoneal vancomycin (Vancoled). Perit Dial Int 1987;7:114–118.
Piraino B, Bernardini J, Holley JL, Perlmutter JA. Increased risk of Staphylococcus epidermidis peritonitis in patients on dialysate containing 1.25 mmol/L calcium. Am J Kidney Dis 1992;19:371–374.
Piraino B, Perlmutter JA, Holley JL, Bernardini J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial Int 1993;13(Suppl 2):s332–s334.
Plum J, Fußhöller A, Schoenicke G, Busch T, Erren C et al. In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Nephrol Dial Transplant 1997;12:1652–1660.
Polk RE. Comment: aminoglycoside dosing considerations. Ann Pharmacother 1993;27:982–983.
Ponferrada LP, Prowant BF, Rackers JA, Pickett B, Satalowich R et al. A cluster of Gram-negative peritonitis episodes associated with reuse of Homechoice cycler cassettes and drain lines. Perit Dial Int 1996;16:636–638.
Poole-Warren L, Farrell PC. Role of vaccination in prevention of staphylococcal peritonitis in CAPD. Perit Dial Int 1993;13:1–6.
Powell D, San Luis E, Calvin S, McDaid T, Potter D. Peritonitis in children undergoing continuous ambulatory peritoneal dialysis. Am J Dis Child 1985;139:29–32.
Principi N. New trends in pediatric antibiotic therapy. Drugs Under Exp Clin Res 1987;13:589–593.
Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once versus twice daily gentamicin in patients with serious infections. Lancet 1993;341:335–339.
Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV; Vancomycin. Clin Pharmacokin 1991;20:463–376.
Pulliam JP, Vernon DD, Alexander SR, Hartstein AI, Golper TA. Non-tuberculous mycobacterial peritonitis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1983;2:610–614.
Reuman PD, Neiberger R, Kondor DA. Intraperitoneal and intravenous fluconazole pharmacokinetics in a pediatric patient with end stage renal disease. Pediatr Infect Dis J 1992;11:132–133.
Richards GK, Morcos RJ, Gagnon RF. The differential activity of aminoglycoside antibiotics with Rifampin explored in a kinetic In Vitro model of implant-associated infection (Staphylococcus epidermidis). Adv Perit Dial 1994;10:183–188.
Robitailli P, Mérouani A, Clermont MJ, Hébert E. Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience. Perit Dial Int 1995;15:77–79.
Rossi TM, Cumella J, Baswell D, Park B. Case report: Ascites as a presenting sign of peritonitis in chronic granulomatous disease of childhood. Clin Pediatr 1987;26:544–545.
Rybak MJ, Albrecht LM, Boike SC et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679–687.
Salmon RF, Arant BS. Aminoglycoside-related neurosensory hearing loss (NHL) in pediatric dialysis patients. Abstract. Kidney Int 1988;33:249.
Sandoe JA, Gokal R, Struthers JK. Vancomycin-resistant enterococci and empirical vancomycin for CAPD peritonitis. Perit Dial Int 1997;17:617–618.
Sanyal D, Williams AJ, Johnson AP, George RC. The emergence of vancomycin resistance in renal dialysis. J Hops Infect 1993;24:167–173.
Sardegna KM, Beck AM, Strife CF. Prophylactic antibiotics reduce peritonitis events following PD catheter placement in children. Perit Dial Int 1996; 16(Suppl 2):s43.
Schaefer F, Klaus G, Müller-Wiefel DE, Mehls O, and Mid European Study Group for Pediatric CAPD/CCPD. Randomized, prospective, multicenter trial on treatment of CPD-associated peritonitis with continuous vs. intermittent vancomycin/teicoplanin and ceftazidime in children. Perit Dial Int 1995;15(Suppl 4):s101.
Schambye HT, Pedersen FB, Wang P. Cytotoxicity of continuous ambulatory peritoneal dialysis (CAPD) solutions. A biocompatibility study involving human polymorphonuclear granulocytes rather than laboratory animals. ATLA 1992;20:275–279.
Schmelter RF, Dirksen JW, Stalp JT, Augustine SC, DuBe JB. Effect of heparin on radioimmunoassay of gentamicin. Am J Hosp Pharm 1981;38:534–537.
Schröder CH, Severijnen RS, de Jong MC, Monnens LA. Chronic tunnel infections in children: removal and replacement of the continuous ambulatory peritoneal dialysis catheter in a single operation. Perit Dial Int 1993;13:198–200.
Schröder CH, Vervoort PJ, Potting CM. Peritonitis in children treated with peritoneal dialysis. Perit Dial Int 1996;16(Supp 12):s44.
Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. Medical Intell 1987;316:927–931.
Scott PMJ, Griffiths MV. A clinical review of ototoxicity. Clin Otolaryng 1994;19:3–8.
Searle M, Venkat Raman G. Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 1985;23:241–244.
Sewell DL, Golper TA, Brown SD, Nelson E, Knower M et al. Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am J Kidney Dis 1983;3:209–212.
Sewell DL, Golper TA, Hulman PB et al. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. Perit Dial Int 1990;10:49–52.
Shemin D, Maaz D. Gram-negative peritonitis in peritoneal dialysis: improved outcome with intraperitoneal ceftazidime. Perit Dial Int 1996; 16:638–641.
Shusterman NH, Jacobs J. Management of refractory peritonitis to maintain the peritoneum for subsequent dialysis. Perit Dial Int 1992;12:211–213.
Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 1987;57:239–247.
Sojo ET, Wainberg ES, Piantanida JJ, Rivas ME, Mendilaharzu F. Successful treatment of a child with Candida peritonitis during C.A.P.D. without removing the catheter. Perit Dial Int 1986;6:104–105.
Steele RW, Rearns GL. Antimicrobial therapy for pediatric patients. Pediatr Clin North Am 1989;36:1321–1349.
Stein A, Baker F, Moorhouse J, Walls J. Peritonitis rate: Traditional versus low calcium dialysate. Am J Kidney Dis 1995;26:632–633.
Swartz R, Messana J, Reynolds J, Ranjit U. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991;40:1160–1165.
Swinney VR, Rudd CC. Nephrotoxicity of vancomycin-gentamicin therapy in pediatric patients. J Pediatr 1987;110:497–498.
Tan D, Fein PA, Jorden A, Avram MM. Successful treatment of tuberculous peritonitis while maintaining patient on CAPD. Adv Perit Dial 1991;7:102–104.
Tang S, Lo CY, Lo WK, Chan TM. Resolution of eosinophilic peritonitis with ketotifen. Am J Kidney Dis 1997;30:433–436.
Tapaneya-Olarn C, Tapaneya-Olarn W. Primary peritonitis in childhood nephrotic syndrome: a changing trend in causative organisms. J Med Assoc Thailand 1991;74:502–506.
Taylor PC. Routine laboratory diagnosis of continuous ambulatory peritoneal dialysis peritonitis using centrifugation/Lysis and Saponin-containing media. Eur J Clin Microbiol Infect Dis 1994;13:249–252.
Termeer A, Hoitsma AJ, Koene RAP. Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients. Transplantation 1986;42:220–221.
Thakur SS, Unikowsky B, Prichard S. Eosinophilic peritonitis in CAPD: treatment with Prednisone and Diphenhydramine. Perit Dial Int 1997;17:402–403.
Tranæus A, Heimbürger O, Lindholm B. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit Dial Int 1989;9:179–190.
Tranæus A. Peritonitis in continuous peritoneal dialysis. Thesis. Stockholm. Reproprint AB, 1990.
Tranæus A. What is the optimal treatment of peritontis? Presentation at 7th Cong of Int Soc for Perit Dial, Stockholm 1995.
Troidle L, Kliger AS, Gorban-Brennan N, Fikrig M, Golden M et al. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996;50:1368.
Tsuen-Chiuan T, Jin-Cherng HSU, Li-Hua C, Meng-Lin L. Tuberculous peritonitis in a child undergoing continuous ambulatory peritoneal dialysis. Acta Pediatr Sin 1994;35:455–459.
Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. Pediatr Nephrol 1997;11:768–772.
Tyler LS, Render TL, Davis RB. Effect of gentamicin on heparin activity. Am J Hosp Pharm 1981;38:537–540.
Tzamaloukas AH; Murata GH, Fox L. Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters. Perit Dial Int 1993,13(Suppl 2):s338–s340.
van Asseldonk JP, Schröder CH, Severijnen RS, de Jong MC, Monnens LA. Infectious and surgical complications of childhood continuous ambulatory peritoneal dialysis. Eur J Pediatr 1992;151:377–380.
Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM et al. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother 1994;33:811–821.
van der Hulst RJ, Boeschoten EW, Nielsen FW, Struijk DG, Dreschler WD et al. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL 1991;53:19–22.
Vas SI. Peritonitis. In: Nolph KD, ed. Peritoneal Dialysis. Dordrecht; Kluwer Academic Publishers, 1989:261–288.
Vas SI. Single daily dose of aminoglycosides in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 1993;13(Suppl 2):s355–s356.
Vas SI. Renaissance of tuberculosis in the 1990s: lessons for the nephrologist. Perit Dial Int 1994;14:209–214.
Vas SI. Treatment of peritonitis: How are we doing? Perit Dial Int 1995;15:201–202.
Vas SI. The diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. Semin Dial 1995;8:232–237.
Vas S, Bargman J, Oreopoulos DG. Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily dose of antibiotics. Perit Dial Int 1997;17:91–94.
Verrina E, Edefonti A, Bassi S, Perfumo F, Zacchello G et al. Peritonitis in children undergoing chronic peritoneal dialysis (CPD): data from the Italian registry of pediatric CPD. Adv Perit Dial 1992;8:419–422.
Verrina E, Bassi S, Perfumo F, Edefonti A, Zacchello G et al. Analysis of complications in a chronic peritoneal dialysis pediatric patient population. Perit Dial Int 1993;13(Suppl 2):s257–s259.
Viganò A, Principi N, Brivio L, Tommasi P, Stasi P et al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 miligrams per kilogram thrice daily for treatment of Gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992;36:1499–1503.
Viscoli C, Gargani G, Facco F, Mantero E, Tuo P et al. Evaluation of ceftazidime in the treatment of 80 infectious episodes in compromised children. Int J Clin Pharmacol Ther Toxicol 1985;23:629–634.
Vondracek TG. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 1995;29:415–424.
Wadhwa NK, Heesuck S, Cabralda T. Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients. Adv Perit Dial 1996;12:189–191.
Waite NM, Johnson MD, Webster NR, Fong IW. Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis. Perit Dial Int 1993;13:50–54.
Wanten GJ, van Oost P, Schneeberger PM, Koolen MI. Nasal carriage and peritonitis by staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study. Perit Dial Int 1996; 16:352–356.
Warady BA, Campoy SF, Gross SP, Sedman AB, Lum GM. Peritonitis with continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. J Pediatr 1984;105:726–730.
Warady BA, Reed L, Murphy G, Kastetter S, Karlsen E et al. Aminoglycoside ototoxicity in paediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 1993,7:178–181.
Warady BA, Sullivan EK, Alexander SR. Lessons from the peritoneal dialysis patient database: A report of the North American pediatric renal transplant cooperative study. Kidney Int 1996;49(Suppl 53):s68–s71.
Watkins S, Sullivan K. Risk factors for peritonitis in North American children receiving peritoneal dialysis: a report of the North Amerian pediatric renal transplant cooperative study. Presentation at the 17th Ann Conf on Perit Dial, Denver, 1997.
Watson AR, Vigneux A, Bannatyne RM, Balfe JW. Peritonitis during continuous ambulatory peritoneal dialysis in children. Can Med Assoc J 1986;134:1019–1022.
Weber J, Kuhlmann U. Intraperitoneal cefazolin and gentamicin in the management of CAPD-related peritonitis. Contrib Nephrol 1991;89:108–118.
Were AJ, Marsden A, Tooth A, Ramsden R, Mistry CD et al. Netilmycin and vancomycin in the treatment of peritonitis in CAPD patients. Clin Nephrol 1992;37:209–213.
Whelton A. Therapeutic initiatives for the avoidance of aminoglycoside toxicity. J Clin Pharmacol 1985;25:67–81.
White R, Abreo K, Flanagan R, Gadallah M, Krane K et al. Non tuberculous mycobacterial infections in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1993;232:581–587.
Wong V, Ross L, Opas L, Lieberman E. Rhodotorula rubra peritonitis in a child undergoing intermittent cycling peritoneal dialysis. J Infect Dis 1988;157:393–394.
Wong PN, Mak SK, Lee KF, Fung LH, Wong AK. A prospective study of vancomycin-(Vancoled-) induced chemical peritonitis in CAPD patients. Perit Dial Int 1997;17:202–204.
Yoshimura K, Toki K, Koide T, Ashino N, Maki I. Infantile granulomatous urachal abscess with acute localized peritonitis and appendicitis. Int J Urol 1994;1:352–354.
Záruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years’ experience. Am J Kidney Dis 1991;17:43–46.
Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994;33:959–967.
Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991;18:225–231.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tranæus, A. (1998). Peritonitis in Paediatric Continuous Peritoneal Dialysis. In: Fine, R.N., Alexander, S.R., Warady, B.A. (eds) CAPD/CCPD in Children. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4931-4_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4931-4_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7237-0
Online ISBN: 978-1-4615-4931-4
eBook Packages: Springer Book Archive